Immunic, Inc.
IMUX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $35 |
| Gross Profit | $0 | $0 | $0 | -$35 |
| % Margin | – | – | – | – |
| R&D Expenses | $20,012 | $21,369 | $21,533 | $21,617 |
| G&A Expenses | $0 | $5,714 | $5,292 | $0 |
| SG&A Expenses | $5,981 | $5,714 | $5,292 | $3,979 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $25,993 | $27,083 | $26,825 | $25,596 |
| Operating Income | -$25,993 | -$27,083 | -$26,825 | -$25,631 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $414 | $263 | $1,352 | $456 |
| Pre-Tax Income | -$25,579 | -$26,820 | -$25,473 | -$25,175 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$25,579 | -$26,820 | -$25,473 | -$25,175 |
| % Margin | – | – | – | – |
| EPS | -0.13 | -0.2 | -0.25 | -0.28 |
| % Growth | 35% | 20% | 10.7% | – |
| EPS Diluted | -0.13 | -0.2 | -0.25 | -0.28 |
| Weighted Avg Shares Out | 193,898 | 132,175 | 101,344 | 90,151 |
| Weighted Avg Shares Out Dil | 193,898 | 132,175 | 101,344 | 90,151 |
| Supplemental Information | – | – | – | – |
| Interest Income | $419 | $241 | $183 | $429 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $43 | $43 | $35 |
| EBITDA | -$25,579 | -$27,040 | -$26,782 | -$25,140 |
| % Margin | – | – | – | – |